Black Bird Biotech, Inc.
BBBT
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -84.82% | -58.25% | -46.38% | -46.46% | -44.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.82% | -58.25% | -46.38% | -46.46% | -44.97% |
| Cost of Revenue | -79.84% | -68.45% | -66.80% | 1,466.67% | -79.97% |
| Gross Profit | -89.55% | -43.09% | 91.96% | -183.53% | 187.58% |
| SG&A Expenses | -93.39% | -78.18% | -82.42% | -83.82% | -49.85% |
| Depreciation & Amortization | -95.05% | -96.65% | -96.65% | -96.64% | -32.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -92.75% | -79.00% | -82.55% | -79.52% | -52.85% |
| Operating Income | 93.89% | 80.34% | 83.54% | 80.66% | 53.81% |
| Income Before Tax | 41.64% | 62.30% | 60.19% | 72.79% | 50.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.64% | 62.30% | 60.19% | 72.79% | 50.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.64% | 62.30% | 60.19% | 72.79% | 50.23% |
| EBIT | 93.89% | 80.34% | 83.54% | 80.66% | 53.81% |
| EBITDA | 126.67% | 95.94% | 116.16% | 79.82% | 55.82% |
| EPS Basic | 87.50% | 82.35% | 72.73% | 82.35% | 65.22% |
| Normalized Basic EPS | 80.00% | 81.82% | 71.43% | 78.95% | 64.29% |
| EPS Diluted | 87.50% | 82.35% | 72.73% | 82.35% | 65.22% |
| Normalized Diluted EPS | 100.00% | 90.00% | 66.67% | 78.95% | 69.23% |
| Average Basic Shares Outstanding | 397.18% | 105.13% | 43.80% | 60.28% | 49.49% |
| Average Diluted Shares Outstanding | 472.32% | 233.89% | 25.06% | 60.28% | 56.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |